ISRCTN57858356未知2 期
A phase Ib/II trial of CA4P (combretastin A-4 phosphate) in combination with carboplatin and paclitaxel chemotherapy in patients with advanced cancer and advanced ovarian carcinoma
East and North Hertfordshire Hospitals NHS Trust (UK)0 个研究点目标入组 42 人开始时间: 2010年3月31日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. A minimum four-week interval must have passed from the time a patient last received chemotherapy, immunotherapy or radiotherapy prior to the first dose of study drugs (six weeks for therapy known to be associated with delayed toxicity such as nitrosoureas or mitomycin-C)
- •2. For entry into the phase II study: patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer who have relapsed following treatment with a platinum containing regime in the adjuvant or metastatic setting, with a progression-free interval (FPI) of less than 6 months.
- •3. Radiologically measurable disease and/or evaluable by Ca 125. To be evaluable for response by CA-125 requires 2 pre-treatment samples greater than twice the upper limit of normal.
- •4. Age 18 years or older
- •5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2
- •6. Life expectancy greater than 12 weeks
- •7. Adequate bone marrow function:
- •7.1. Absolute granulocyte count (neutrophils and bands) greater than 1500 cells/mm^3
- •7.2. Platelet count greater than 100,000 cells/mm^3
- •8. Adequate hepatic function:
- •8.1. Total bilirubin less than 1.5 mg/dl
- •8.2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 2.5 x upper limit of normal
- •9. Adequate renal function: Glomerular Filtration Rate measured by EDTA
- •clearance greater than 50 ml/min
- •10. Patients must provide written and voluntary informed consent and be available for periodic follow-up
- •11. Fertile patients must abstain from sexual intercourse or use effective birth control
- •12. All women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test documented within 72 hours prior to receiving cycle 1
排除标准
- •1. Serious intercurrent infection(s) or other nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardised by the complications of this therapy
- •2. Grade 2 (CTC v 3.0) or greater pre-existing peripheral neuropathy (motor or sensory)
- •3. Active brain metastasis, including symptomatic involvement, evidence of cerebral oedema by CT or MRI, radiographic evidence of progression since definitive therapy, or continued requirement for corticosteroids
- •4. Major surgery within four weeks prior to receiving cycle 1
- •5. Symptomatic peripheral vascular disease or cerebrovascular disease
- •6. Prior radiation involving > 30% of the bone marrow
- •7. Patients who have had any clinically apparent ischaemic or vascular damage from previous radiotherapy. Patients who have had radical radiotherapy to the thorax or abdomen at any time or post-operative radical radiotherapy to the pelvis. Palliative radiotherapy treatments are acceptable. Patients with rectal primaries who have received pre-operative pelvic radiotherapy or chemoradiation are eligible if the small bowel was mobile and not stuck to the tumour.
- •8. Psychiatric disorders or other conditions rendering patients incapable of complying with the requirements of the protocol
- •9. Pregnant or breast-feeding women
- •10. History of angina (stable or more severe, even if controlled with medications), myocardial infarction, CHF, non-controlled atrial arrhythmias or clinically significant arrhythmias including conduction abnormality, nodal junctional arrhythmias and dysrhythmias, sinus bradycardia or tachycardia, supraventricular arrhythmias, atrial fibrillation or flutter, syncope or vasovagal episodes
- •11. MUGA scan revealing significant heart wall abnormality or heart muscle damage
- •12. Uncontrolled hypertension (defined as blood pressure consistently greater than 150/100 irrespective of medication)
- •13. Uncontrolled hypokalemia and/or hypomagnesemia
- •14. ECG with evidence of prior myocardial infarction (e.g., significant Q waves), QTc > 450 msec or other clinically significant abnormalities
- •15. Patients taking any drug(s) known to prolong the QTc interval, which cannot be interrupted for at least four days during each 21-day treatment cycle. Patients with conditions associated with QTc prolongation
- •16. Concurrent investigational therapy
- •17. Concurrent antineoplastic therapy (radiation therapy, cytotoxic or biologic therapy)
- •18. Concurrent hormonal therapy with the exception of GnRH agonists in patients with hormone refractory prostate cancer, HRT, oral contraceptives, and megestrol acetate used for anorexia/cachexia
- •19. Receiving anticoagulation with warfarin, heparin or low molecular weight heparin other than low dose (1 mg) warfarin for maintenance of Hickman line patency
- •20. No previous high-dose chemotherapy with autologous bone marrow transplant (HDC-ABMT) or similar high-dose therapies
研究者
相似试验
已完成
2 期
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid TumorsCancerTumorNCT00113438Mateon Therapeutics13
已完成
2 期
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung CancerTumorsNCT00653939Mateon Therapeutics63
终止
1 期
A Study of LY2510924 and Durvalumab in Participants With Solid TumorsSolid TumorNCT02737072Eli Lilly and Company9
未知
2 期
Phase II study of KW-0761JPRN-jRCT2080220744Kyowa Hakko Kirin Co., Ltd.25
未知
2 期
Phase II study of KW-0761 in subjects with CCR4-positive peripheral T/NK-cell lymphomaJPRN-jRCT2080221219Kyowa Hakko Kirin Co., Ltd.